Jasper Therapeutics Inc. (JSPR)
$0.48
$-0.03
(-5.51%)
As on 03-Nov-2026 16:15EST
Market cap
$17 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
12.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.6 %
-
ROCE
-- %
-
Industry P/E
43.9
-
EV/EBITDA
-3.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
33,274,561
5 Years Aggregate
CFO
$-151.84 Mln
EBITDA
$-186.70 Mln
Net Profit
$-149.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics (JSPR)
| -73.8 | -15.0 | -23.8 | -78.9 | -58.9 | -65.0 | -- |
|
BSE Sensex*
| -8.8 | 7.4 | -1.8 | -8.1 | 6.3 | 5.3 | 10.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Jasper Therapeutics (JSPR)
| -91.4 | 168.8 | 63.4 | -93.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics (JSPR)
|
0.5 | 17.3 | 0.0 | -31.8 | -- | -1142 | -- | 12.3 |
| 20.2 | 7,491.9 | 3,117.6 | 157.4 | 14.7 | -- | 43.9 | 226.9 | |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 16.2 | 32.7 | 38.3 | 12.7 | |
| 139.6 | 7,565.4 | 776.6 | -191.6 | -24.0 | -223.4 | -- | 90.8 | |
| 74.0 | 14,600.3 | 945.5 | -570.2 | -47.1 | -- | -- | 123.7 | |
| 81.9 | 8,768.9 | 830.8 | 54.9 | 3.2 | 8.1 | 180.3 | 12.4 | |
| 24.6 | 11,611.2 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.7 | |
| 8.6 | 5,512.7 | 7,430.4 | 452.5 | 17.6 | 7 | 10.5 | 0.9 | |
| 313.5 | 6,434.2 | 253.8 | 51.5 | 38.8 | 5.3 | 34 | 6.7 | |
| 140.3 | 10,129.5 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 22.7 |
Shareholding Pattern
View DetailsAbout Jasper Therapeutics (JSPR)
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has... demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California. Read more
-
President, CEO & Director
Mr. Ronald A. Martell
-
President, CEO & Director
Mr. Ronald A. Martell
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Jasper Therapeutics (JSPR)
What is the current share price of Jasper Therapeutics Inc (JSPR) Today?
The share price of Jasper Therapeutics Inc (JSPR) is $0.48 (NASDAQ) as of 03-Nov-2026 16:15 EST. Jasper Therapeutics Inc (JSPR) has given a return of -58.89% in the last 3 years.
What is the current PB & PE ratio of Jasper Therapeutics Inc (JSPR)?
Since, TTM earnings of Jasper Therapeutics Inc (JSPR) is negative, P/E ratio is not available.
The P/B ratio of Jasper Therapeutics Inc (JSPR) is 12.31 times as on 30-Oct-2026, a 54 premium to its peers’ median range of 8.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.69 |
12.64 |
2024 |
-4.50 |
5.20 |
2023 |
-0.14 |
0.11 |
2022 |
-0.05 |
0.05 |
2021 |
-0.21 |
0.09 |
What is the 52 Week High and Low of Jasper Therapeutics Inc (JSPR)?
The 52-week high and low of Jasper Therapeutics Inc (JSPR) are Rs 2.42 and Rs 0.32 as of 04-Nov-2026.
What is the market cap of Jasper Therapeutics Inc (JSPR)?
Jasper Therapeutics Inc (JSPR) has a market capitalisation of $ 17 Mln as on 30-Oct-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Jasper Therapeutics Inc (JSPR)?
Before investing in Jasper Therapeutics Inc (JSPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.